Recent studies led by researchers in Singapore have made significant strides in developing new treatments for specific cancers that predominantly affect women, including clear cell ovarian cancer and triple-negative breast cancer. These advancements bring renewed hope for patients facing difficult diagnoses.
Promising Outcomes in Clear Cell Cancer Treatment
One notable study investigated a combination therapy involving pembrolizumab and lenvatinib, which has shown encouraging results for patients battling recurrent clear cell endometrial and ovarian cancers that have proven resistant to conventional treatments. This research, known as the Lara trial, was orchestrated by the Asia-Pacific Gynecologic Oncology Trials Group, co-founded by Associate Professor David Tan, a senior consultant at the National University Cancer Institute, Singapore.
Clear cell cancers, particularly of the ovary and endometrium, often yield poor responses to standard chemotherapy. This ineffectiveness can be attributed to the unique characteristics of these tumors, including atypical cellular structures and abnormal blood vessel development, as well as a tumor environment that allows cancer cells to escape immune detection.
Disproportionate Impact on Asian Populations
The prevalence of clear cell cancers is notably higher in Asian populations, comprising nearly 30 percent of ovarian cancer cases in Japan, in stark contrast to about 12 percent in Western nations. Prof. Tan points out that this disparity may be linked to endometriosis, a condition more commonly found among Asian women, where uterine tissue grows outside the uterus.
In the Lara trial, lenvatinib functions by inhibiting signals that promote tumor growth while simultaneously enhancing access for immune cells within the tumor environment. Pembrolizumab works to amplify the immune system’s ability to identify and attack cancer cells. While this drug combination is already approved for recurrent clear cell endometrial cancer, it has yet to receive clearance for clear cell ovarian cancer treatments.
Trial Results and Patient Experiences
The trial, which ran from 2021 to 2023 across Singapore and South Korea, involved collaboration between clinicians and scientists from both countries, with results published in The Lancet Oncology. Of the 25 patients enrolled, 40 percent experienced tumor reductions of 30 percent or more within the first 24 weeks, while half of the participants exhibited no disease progression for over six months.
One participant, referred to as Michelle, joined the trial after two unsuccessful standard chemotherapy regimens. Although she had to discontinue the trial after one month due to elevated liver enzymes, she observed persistent benefits, with tumors in her neck and pelvic lymph nodes continuing to shrink. “I’m very grateful to experience the magic of this pembrolizumab and lenvatinib,” expressed the 49-year-old, hoping the treatment could soon be added to the Health Ministry’s list of approved cancer drugs.
Prof. Tan highlighted that a recent study in the United States echoed the Lara trial’s findings, further solidifying their significance. Efforts are underway to incorporate this combination therapy into the US National Comprehensive Cancer Network guidelines, which would enhance its accessibility for patients in Singapore.
Advances in Triple-Negative Breast Cancer Treatment
In a separate trial focusing on patients with untreated, advanced triple-negative breast cancer, researchers reported substantial improvements in survival rates. This aggressive cancer subtype is particularly concerning, affecting younger women and often associated with early recurrence and lower survival rates. It accounts for roughly 15 percent of all breast cancer cases in Singapore.
Dr. Rebecca Dent, the deputy clinical CEO at the National Cancer Centre Singapore, expressed optimism about datopotamab deruxtecan, an antibody-drug conjugate that targets and destroys cancer cells while preserving healthy tissue. Although currently approved for other breast cancer types, it remains unapproved for triple-negative cases.
Key Findings and Future Prospects
The multi-national study included 644 patients and revealed that progression-free survival—an indicator of how long patients live without disease worsening—doubled to a median of 10.8 months with Dato-DXd compared to traditional chemotherapy. Furthermore, 63 percent of patients experienced a significant reduction in tumor size with the new drug, in contrast to only 29 percent with chemotherapy.
As Dato-DXd undergoes review by the US Food and Drug Administration and Singapore’s Health Sciences Authority as a first-line treatment for triple-negative breast cancer, Dr. Dent is hopeful for its approval within the coming year. Highlighting the consistent effectiveness of antibody-drug conjugates, she remarked, “One thing that’s very consistent for all of these antibody-drug conjugates is that you can see a sustained response.”
Conclusion
The groundbreaking research from Singapore offers a glimmer of hope for women facing challenging cancer diagnoses. With these innovative treatments on the horizon, there is potential for improved outcomes and a brighter future for patients battling these aggressive forms of cancer. Continued efforts in research and clinical trials will be crucial in making these advancements accessible to those in need.
- Significant advancements in treating clear cell ovarian and triple-negative breast cancers.
- Combination therapies show promising results in clinical trials.
- Ongoing collaboration among international researchers enhances treatment options.
- Sustained responses from new therapies offer hope for long-term effectiveness.
- Increased focus on cancers disproportionately affecting Asian women.
Read more → www.straitstimes.com